Evidence map›Paper›PMID 39004237›Full record

ArticleAnnals of epidemiology2024

COVID-19 vaccination initiation and completion in a multicenter cohort study of insured US transgender and cisgender adults.

Meron Siira, Darios Getahun, Michael J Silverberg, Vin Tangpricha, Michael Goodman, Howa Yeung

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Meron SiiraDepartment of Dermatology, Emory University School of Medicine, Atlanta, GA, USA.
Darios GetahunDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, USA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Michael J SilverbergDepartment of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Vin TangprichaDivision of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Michael GoodmanDepartment of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.
Howa YeungDepartment of Dermatology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: howa.yeung@emory.edu.

Funding

Characteristics of COVID-19 in transgender peopleR01AG066956 · NIA · EMORY UNIVERSITY · PI GOODMAN, MICHAEL · 2021 to 2025
$3.5M
Epidemiology, impact, and experience of acne in transgender personsK23AR075888 · NIAMS · EMORY UNIVERSITY · PI YEUNG, HOWA · 2020 to 2024
$789k
Cohort study of mortality and morbidity in transgender personsR21HD076387 · NICHD · EMORY UNIVERSITY · PI GOODMAN, MICHAEL · 2013 to 2014
$451k
NIAMS NIH HHS K23 AR075888NIAMS NIH HHS L30 AR076081NIA NIH HHS R01 AG066956NICHD NIH HHS R21 HD076387
6 · The paper itself

Abstract

purposeTransgender and gender-diverse (TGD) people may have been disproportionately impacted by the COVID-19 pandemic, yet little is known about vaccination status in this population. This multicenter cohort study of insured adults examined the rates of COVID-19 vaccine initiation and completion in TGD persons compared to matched cisgender persons.

methodsA cohort of TGD persons and matched cisgender persons enrolled in Kaiser Permanente health plans in Northern and Southern California between 12/1/2020 and 7/31/2021 were analyzed. COVID-19 vaccination initiation and completion rates were compared across groups using Cox regression models.

resultsAmong transmasculine persons, the HR (95 % CI) estimates for COVID-19 vaccination initiation and completion were, respectively, 1.35 (1.30-1.40) and 1.78 (1.71-1.85) compared with cisgender women and 1.34 (1.29-1.40) and 1.81 (1.73-1.88) compared with cisgender men. Among transfeminine persons, the corresponding HRs (95 % CIs) for vaccination initiation and completion were 1.35 (1.30-1.40) and 1.78 (1.71-1.85) compared with cisgender women and 1.34 (1.29-1.40) and 1.81 (1.73-1.88) compared with cisgender men.

conclusionFindings from this cohort of insured adults demonstrated that TGD persons initiated and completed COVID-19 vaccination at higher rates compared to matched cisgender persons. Further work is needed to understand vaccination rates and determinants in the broader TGD populations.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Transgender PersonsVaccinationAdultCaliforniaCohort StudiesFemaleHumansMaleMiddle AgedUnited StatesVaccination CoverageYoung AdultCOVID-19 VaccinesCOVID-19 vaccineshealth equityHealth services for transgender transgenderpersonsTransgender persons

Identifiers

PMID39004237
PMCPMC12090839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.